Outlook Therapeutics, Inc. Common Stock OTLK
Analyst Ratings
- Consensus
- Moderate Buy — 2 Buy · 2 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $4.28 (+829.3% upside)
Key Stats
- Today's Range
- $0.45 – $0.48
- 50-Day Range
- $0.44 – $0.74
- 52-Week Range
- $0.16 – $2.54
- Volume
- 2.53 million shs
- Average Volume
- 4.18 million shs
- Market Cap
- $114.23 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.03%
- Days to Cover
- 1.44
About Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Related Stocks
Compare head-to-head: OTLK vs AMGN·OTLK vs MRNA·OTLK vs HALO·OTLK vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.